TW202045545A - 白蛋白結合抗體及其用途 - Google Patents

白蛋白結合抗體及其用途 Download PDF

Info

Publication number
TW202045545A
TW202045545A TW109105677A TW109105677A TW202045545A TW 202045545 A TW202045545 A TW 202045545A TW 109105677 A TW109105677 A TW 109105677A TW 109105677 A TW109105677 A TW 109105677A TW 202045545 A TW202045545 A TW 202045545A
Authority
TW
Taiwan
Prior art keywords
amino acid
seq
acid sequence
albumin
variant
Prior art date
Application number
TW109105677A
Other languages
English (en)
Chinese (zh)
Inventor
子洋 鐘
葉帆
馬修 希格
嘉寧 黃
艾瑞克 廖
雨敏 李
Original Assignee
美商安維塔生物科學股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商安維塔生物科學股份有限公司 filed Critical 美商安維塔生物科學股份有限公司
Publication of TW202045545A publication Critical patent/TW202045545A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
TW109105677A 2019-02-22 2020-02-21 白蛋白結合抗體及其用途 TW202045545A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962809475P 2019-02-22 2019-02-22
US62/809,475 2019-02-22

Publications (1)

Publication Number Publication Date
TW202045545A true TW202045545A (zh) 2020-12-16

Family

ID=72144485

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109105677A TW202045545A (zh) 2019-02-22 2020-02-21 白蛋白結合抗體及其用途

Country Status (6)

Country Link
US (1) US12479909B2 (https=)
EP (1) EP3927740A4 (https=)
JP (1) JP2022520998A (https=)
CN (1) CN113508134B (https=)
TW (1) TW202045545A (https=)
WO (1) WO2020172528A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
EP3806889A4 (en) * 2018-06-18 2022-07-13 Anwita Biosciences, Inc. CYTOKI FUSION PROTEINS AND USES THEREOF
TW202128961A (zh) 2019-11-20 2021-08-01 美商安維塔生物科學股份有限公司 細胞激素融合蛋白及其醫藥組合物及治療應用
US11897930B2 (en) 2020-04-28 2024-02-13 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
EP4171611A4 (en) 2020-07-30 2024-10-02 Anwita Biosciences, Inc. Interleukin-22 fusion proteins, and their pharmaceutical compositions and therapeutic applications
CN116419973A (zh) * 2020-10-02 2023-07-11 新加坡科技研究局 用于蛋白质生产和筛选的表达系统
JP2023549537A (ja) * 2020-11-16 2023-11-27 エイビー セラピューティクス インコーポレイテッド 多重特異性抗体およびその使用方法
CN117042788A (zh) * 2020-12-08 2023-11-10 佳努克斯治疗公司 半衰期延长组合物和方法
CN117545504A (zh) * 2021-06-07 2024-02-09 上海济煜医药科技有限公司 抗人血清白蛋白的抗原结合蛋白
JP2025517120A (ja) * 2022-05-05 2025-06-03 インヒブルクス バイオサイエンシズ インコーポレイテッド アルブミン結合ポリペプチド及びその使用
EP4573119A1 (en) * 2022-08-17 2025-06-25 Institut National de la Santé et de la Recherche Médicale Improved anti-albumin nanobodies and their uses
WO2024051796A1 (en) * 2022-09-09 2024-03-14 Wuxi Biologics (Shanghai) Co., Ltd. Albumin binding proteins, fusion proteins and uses thereof
WO2024097639A1 (en) * 2022-10-31 2024-05-10 Modernatx, Inc. Hsa-binding antibodies and binding proteins and uses thereof
JP2026506075A (ja) 2023-02-17 2026-02-20 アブリンクス エン．ヴェー． 新生児型ｆｃ受容体に結合するポリペプチド
WO2024236068A1 (en) * 2023-05-17 2024-11-21 Navigo Proteins Affinity ligand for a single chain antibody fragment specific for serum albumin
NL2036011B1 (en) 2023-10-12 2025-04-30 Synapse Res Institute Molecules for reversing anti-coagulant activity of direct oral anticoagulants

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004041867A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders
EP2102244A2 (en) 2006-12-19 2009-09-23 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
EP2692736B1 (en) 2008-10-14 2018-04-18 National Research Council Of Canada Bsa-specific antibodies
JP2012532620A (ja) 2009-07-16 2012-12-20 グラクソ グループ リミテッド 改良型抗血清アルブミン結合単一可変ドメイン
US9556273B2 (en) * 2010-03-29 2017-01-31 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
JP2013537421A (ja) * 2010-08-20 2013-10-03 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 改良された抗血清アルブミン結合変異体
AU2013201422B2 (en) * 2012-01-23 2015-04-09 Ablynx Nv Sequences directed against hepatocyte growth factor (HFG) and polypeptides comprising the same for the treatment of cancers and/or tumors
BR112014020694A2 (pt) * 2012-02-15 2018-05-08 Amunix Operating Inc. proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a
WO2016034968A1 (en) 2014-09-02 2016-03-10 Pfizer Inc. Therapeutic antibody
WO2016081639A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Antibodies against bace1 and use thereof for neural disease immunotherapy
EA201792573A1 (ru) * 2015-05-21 2018-04-30 Харпун Терапьютикс, Инк. Триспецифические связанные белки и способы их применения
CN115925919A (zh) * 2015-11-13 2023-04-07 埃博灵克斯股份有限公司 改进的血清白蛋白结合免疫球蛋白可变结构域
JP7101621B2 (ja) * 2016-05-20 2022-07-15 ハープーン セラピューティクス，インク． 単一ドメイン血清アルブミン結合タンパク質
RU2022101604A (ru) * 2016-12-07 2022-03-29 Аблинкс Нв Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином
AU2018265856B2 (en) 2017-05-12 2023-04-27 Harpoon Therapeutics, Inc. Mesothelin binding proteins
DK3661954T3 (da) * 2017-08-03 2022-04-19 Amgen Inc Interleukin-21-muteiner og fremgangsmåder til behandling
CA3076250A1 (en) * 2017-10-02 2019-04-11 Vib Vzw Compounds to inhibit bacterial s-layer protein assembly
EP3806889A4 (en) 2018-06-18 2022-07-13 Anwita Biosciences, Inc. CYTOKI FUSION PROTEINS AND USES THEREOF
TW202128961A (zh) * 2019-11-20 2021-08-01 美商安維塔生物科學股份有限公司 細胞激素融合蛋白及其醫藥組合物及治療應用
EP4171611A4 (en) * 2020-07-30 2024-10-02 Anwita Biosciences, Inc. Interleukin-22 fusion proteins, and their pharmaceutical compositions and therapeutic applications

Also Published As

Publication number Publication date
EP3927740A1 (en) 2021-12-29
CN113508134B (zh) 2024-12-03
US12479909B2 (en) 2025-11-25
CN113508134A (zh) 2021-10-15
WO2020172528A8 (en) 2021-10-07
US20220195021A1 (en) 2022-06-23
JP2022520998A (ja) 2022-04-04
WO2020172528A1 (en) 2020-08-27
EP3927740A4 (en) 2023-03-01

Similar Documents

Publication Publication Date Title
US12479909B2 (en) Albumin binding antibodies and use thereof
JP7544937B2 (ja) Ｔｉｇｉｔに対する単一ドメイン抗体及びその変異体
KR102876940B1 (ko) Lag-3에 대한 단일-도메인 항체 및 이의 용도
TWI905235B (zh) 抗cd93之構築體及其用途
JP2022523710A (ja) Ｃｄ４４に特異的な抗体
CN114907479B (zh) 抗cd112r抗体及其用途
CN114466664A (zh) 施用抗siglec-8抗体和皮质类固醇的方法
CN114829406A (zh) 治疗肠易激综合征和功能性消化不良的方法和组合物
TWI917387B (zh) 抗ｃｄ９３之構築體及其用途
JP2025525291A (ja) ガンマ－デルタｔ細胞受容体に結合する抗体を含む組成物
HK40118288A (zh) 包含结合γ-δ T细胞受体的抗体的组合物
HK40022776A (en) Anti-bcma heavy chain-only antibodies